2-(3-METHOXYCYCLOPENTYL)-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE

Catalog No. :
ACFCIY286
CAS No. :
2304631-38-5
Molecular Formula :
C12H23BO3
Molecular Weight :
226.13

IUPAC Name:2-(3-methoxycyclopentyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

2-(3-METHOXYCYCLOPENTYL)-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$2406.00Login to see priceInquiryInquiry
250mg95%$3610.00Login to see priceInquiryInquiry
1g95%$7221.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(3-METHOXYCYCLOPENTYL)-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE
IUPAC Name2-(3-methoxycyclopentyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
MDL No.MFCD31555340
Molecular FormulaC12H23BO3
Molecular Weight226.13
SMILESCC1(C(C)(OB(O1)C2CC(CC2)OC)C)C
InChI KeyRPNMGXYAXWMSEF-UHFFFAOYSA-N
Synonym1,3,2-Dioxaborolane, 2-(3-methoxycyclopentyl)-4,4,5,5-tetramethyl-;2-(3-METHOXYCYCLOPENTYL)-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE
CAS No.2304631-38-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACFCIY286 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFCIY286 route product structure diagram
    ACFCIY2862304631-38-5
Inquiry

2. ACFCIY286 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFCIY286 route product structure diagram
    ACFCIY2862304631-38-5
Inquiry

Comments (0)